Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats

Yonsei Medical Journal

Volumn 51, Issue 3, 2010, Pages 385-391

  Sung, Joong Kyung ^a   Koh, Jang Hyun ^b   Lee, Mi Young ^a   Kim, Bo Hwan ^a   Nam, Soo Min ^c   Kim, Jae Hyun ^a   Yoo, Jin Hee ^a   Kim, So Hee ^a   Hong, Sun Won ^d   Lee, Eun Young ^e   Choi, Ran ^a   Chung, Choon Hee ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Sun General Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Albumin creatinine ratio; Aldose reductase inhibitor; Diabetic nephropathy; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; CREATININE; FIDARESTAT; GLUCOSE; LOSARTAN; MESSENGER RNA; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECT; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; TREATMENT OUTCOME;

ALDEHYDE REDUCTASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IMIDAZOLIDINES; KIDNEY; LOSARTAN; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954296340     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.3.385     Document Type: Article

References (32)

1. Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994;43:1-8.
2. Yamagishi S, Inagaki Y, Okamoto Y, Amano S, Koga K, Takeeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;227:20309-15.
3. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997;273:H2224-31.
4. Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 1997;46:41-7.
5. Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol 2000;165:617-24.
6. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB- 9195. Diabetologia 1999;42:579-88.
7. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101: 1219-24.
8. Wang L, Kwak JH, Kim SI, He Y, Choi ME. Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem 2004;279:33213-9.
9. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996;98:1667-75.
10. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
11. Cha DR, Kim IS, Kang YS, Han SY, Han KH, Shin C, et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet Med 2005;22:14-20.
12. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-39.
13. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000.
14. Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;36:65-70.
15. Fonseca VA. Clinical diabetes: translating research into practice. Philadelphia: Saunders Elsevier; 2006.
16. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997;99:2192-202.
17. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003;52:864-71.
18. Lane PH, Steffes MW, Mauer SM. Estimation of glomerular volume: a comparison of four methods. Kidney Int 1992;41:1085-9.
19. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987;32:691-9.
20. Ziyadeh FN. The extracelluar matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-44.
21. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989;83:1667-75.
22. Ghahary A, Luo JM, Gong YW, Chakrabarti S, Sima AA, Murphy LJ. Increased renal aldose reductase activity, immunoreactivity, and mRNA in streptozocin-induced diabetic rats. Diabetes 1989;38:1067-71.
23. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109 Suppl 2:S424-37.
24. Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem Cell Biol 1996;74:355-62.
25. Isogai S, Inokuchi T, Ohe K. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 1995;30: 111-6.
26. Obrosova IG. How dose glucose generate oxidative stress in peripheral nerve? Int Rev of Neurobiol 2002;50:3-35.
27. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999;13:23-30.
28. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverse early diabetesinduced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002;16:123-5.
29. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and vivo. J Clin Invest 1996;98:1667-75.
30. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002;82:25-35.
31. Foppiano M, Lombardo G. Worldwide pharmacovigilance system and tolrestat withdrawal. Lancet 1997;349:399-400.
32. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenetic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82:619-28.